A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Jul 24, 2026 to Apr 9, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 6 of 9 entries
    • Site details revised at 15 of 43 sites
    • Publications: details revised at 1 of 1 entry
  2. Trial status: Recruiting to Active, Not Recruitingv3 Show 5 more changesShow less
    • Enrollment target: estimated 720 to confirmed 721
    • Study sites: 30 to 43
    • Primary completion date: Feb 24, 2026 to Jul 24, 2026
    • Study completion date: Apr 13, 2026 to Jul 24, 2026
    • Start date: Jan 25, 2025 to Jan 24, 2025
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 27, 2025 to Jan 25, 2025
    • Secondary endpoints: 8 to 9
    • Site details revised at 30 of 30 sites
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Daiichi Sankyo
70 trials monitored
See 8 trials at risk
This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.
Trial Details
NCT Number NCT06812117
Lead Sponsor Daiichi Sankyo
Conditions
(from sponsor)		 Diabetic Peripheral Neuropathic Pain
Enrollment 721 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov